Bristol Myers Squibb, BioNTech report 36.7% response rate for pumitamig combination in Phase 2 lung cancer trial

• Bristol Myers Squibb and BioNTech reported encouraging Phase 2 results for investigational pumitamig with docetaxel in previously treated advanced lung cancer.
• ROSETTA Lung-107 showed tumor responses across cancer subtypes and PD-L1 expression levels in patients whose disease progressed following immunotherapy with chemotherapy.
• Results presented today at the ESMO Congress 2026 showed encouraging progression-free survival, supporting further development in second-line non-small cell lung cancer.
• The combination had a manageable safety profile, with no new safety signals or pumitamig-related deaths.
• The findings expand pumitamig’s lung cancer evidence base as the partners advance four global Phase 3 trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.